Free Trial

BioAtla (BCAB) Stock Price, News & Analysis

-0.14 (-7.89%)
(As of 03:51 PM ET)
Today's Range
50-Day Range
52-Week Range
724,741 shs
Average Volume
609,036 shs
Market Capitalization
$75.79 million
P/E Ratio
Dividend Yield
Price Target

BioAtla MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
440.0% Upside
$8.67 Price Target
Short Interest
10.81% of Shares Sold Short
Dividend Strength
News Sentiment
0.40mentions of BioAtla in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.72) to ($1.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

575th out of 931 stocks

Biological Products, Except Diagnostic Industry

91st out of 154 stocks

BCAB stock logo

About BioAtla Stock (NASDAQ:BCAB)

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

BCAB Stock Price History

BCAB Stock News Headlines

BioAtla (NASDAQ:BCAB) PT Lowered to $5.00 at JMP Securities
BCAB Stock Earnings: BioAtla Beats EPS for Q1 2024
BioAtla, Inc. Common Stock (BCAB)
BioAtla, Inc. (BCAB)
GRIN, WOOF and MRNS are among after hour movers
BioAtla: Q4 Earnings Insights
See More Headlines
Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.47 per share


Free Float
Market Cap
$82.29 million
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

BCAB Stock Analysis - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings
or view top-rated stocks.

What is BioAtla's stock price target for 2024?

3 equities research analysts have issued twelve-month price objectives for BioAtla's shares. Their BCAB share price targets range from $5.00 to $14.00. On average, they predict the company's stock price to reach $8.67 in the next twelve months. This suggests a possible upside of 440.0% from the stock's current price.
View analysts price targets for BCAB
or view top-rated stocks among Wall Street analysts.

How have BCAB shares performed in 2024?

BioAtla's stock was trading at $2.46 at the beginning of the year. Since then, BCAB stock has decreased by 34.8% and is now trading at $1.6050.
View the best growth stocks for 2024 here

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our BCAB earnings forecast

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) posted its earnings results on Tuesday, March, 26th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.12.

What ETF holds BioAtla's stock?

Formidable ETF holds 114,150 shares of BCAB stock, representing 0.93% of its portfolio.

When did BioAtla IPO?

BioAtla (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.

Who are BioAtla's major shareholders?

BioAtla's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.36%), Acadian Asset Management LLC (0.32%), Tidal Investments LLC (0.30%), Chase Investment Counsel Corp (0.16%), Virtu Financial LLC (0.06%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Christian Vasquez, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCAB) was last updated on 5/28/2024 by Staff

From Our Partners